Autoimmunity Diagnostics Market : Driven by Rising Disease Burden and Advanced Diagnostic Innovations

 The global autoimmunity diagnostics market is projected to grow from USD 5.57 billion in 2025 to USD 8.98 billion by 2031, registering a CAGR of 8.3% during the forecast period. This growth underscores the expanding role of advanced diagnostics in improving patient outcomes and enabling early disease intervention. As autoimmune diseases continue to rise globally, the need for precise and timely diagnostic solutions is becoming a strategic priority for healthcare systems and industry leaders. 

Download PDF Brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=174826519

What is fueling the sustained expansion of the autoimmunity diagnostics market?

The increasing global prevalence of autoimmune disorders—ranging from systemic conditions such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) to organ-specific diseases—is significantly driving demand for reliable diagnostic tools. Why is this trend critical now? Early and accurate detection is essential to managing disease progression, reducing long-term healthcare costs, and improving quality of life for patients.

How are technological advancements reshaping the diagnostic landscape?

Continuous innovation in diagnostic platforms, including advanced immunoassays and autoantibody testing, is enabling faster, more accurate, and earlier detection of autoimmune conditions. At the same time, growing research investments are accelerating the development of next-generation testing methods, while expanding healthcare infrastructure—particularly in emerging markets—is improving access to these critical diagnostic services.

Which product segment is expected to see the fastest growth?

The consumables segment is projected to register the highest CAGR during the forecast period. This growth is driven by the recurring need for reagents, kits, and other single-use consumables required for routine and specialized diagnostic tests. Increasing testing volumes, adoption of advanced immunoassay kits, and a strong preference for contamination-free, high-accuracy solutions are further supporting this segment’s expansion.

Which disease segment presents the strongest growth opportunity?

Organ-specific autoimmune diseases are expected to witness the highest growth rate. Rising prevalence of conditions such as type 1 diabetes, celiac disease, and inflammatory bowel disease (IBD), combined with increasing awareness and adoption of targeted diagnostic approaches, is driving demand. Advances in detecting specific autoantibodies are also enabling more precise and rapid diagnosis, strengthening clinical decision-making.

Speak To Analyst:- https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=174826519

Where is the market seeing the highest regional dominance?

North America accounted for the largest share of the autoimmunity diagnostics market in 2024. This leadership is driven by well-established healthcare infrastructure, high healthcare spending, and a strong presence of leading diagnostic companies. Additionally, the region’s high incidence of autoimmune diseases and continued investments in research and development are expected to sustain growth momentum.

Who are the key players shaping the competitive landscape?

Leading companies include F. Hoffmann-La Roche Ltd., Abbott Laboratories, Revvity, Inc., Thermo Fisher Scientific Inc., Siemens Healthineers AG, Bio-Rad Laboratories, Inc., Danaher Corporation, Werfen S.A., Grifols S.A., and QuidelOrtho Corporation. These organizations are focusing on innovation, expanding product portfolios, and strategic collaborations to strengthen their market position.

Conjugate Vaccines Market : Growing inclusion in national vaccination schedules and advancements in multivalent vaccines

 The global Conjugate vaccines market is projected to grow from USD 15.25 billion in 2025 to USD 21.77 billion by 2030, registering a CAGR of 7.4% during the forecast period. This growth reflects increasing reliance on vaccination programs to reduce disease burden and improve population health outcomes. As global healthcare systems intensify efforts to combat infectious diseases, conjugate vaccines are becoming a cornerstone of preventive care strategies. 

Download PDF Brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=199230303

What is driving sustained growth in the conjugate vaccines market?

A key factor is the high prevalence of vaccine-preventable diseases across both pediatric and adult populations. Governments and global health organizations are expanding national immunization programs, ensuring broader access to life-saving vaccines. Why is this critical now? The heightened focus on preventive healthcare, coupled with rising awareness of infectious disease risks, is accelerating vaccine adoption worldwide.

Which disease segment is leading market demand?

Pneumococcal disease accounted for the largest share of the conjugate vaccines market in 2024. This dominance is driven by the significant incidence of invasive pneumococcal disease (IPD) and strong recommendations for vaccination among vulnerable populations. Routine immunization schedules guided by organizations such as the CDC and ACIP are reinforcing uptake. Additionally, ongoing innovation in multivalent vaccine formulations is enhancing coverage against multiple strains, further strengthening demand.

Who are the primary beneficiaries and growth drivers by end user?

The pediatric segment is expected to register the fastest growth during the forecast period. How is this trend shaping the market? Routine childhood immunization programs, combined with strong government mandates and increasing parental awareness, are driving higher vaccination rates among infants and young children. As healthcare systems prioritize early disease prevention, demand for pediatric conjugate vaccines is expected to rise significantly.

Speak To Analyst:- https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=199230303 

Where is the market seeing the strongest regional performance?

North America accounted for the largest share of the conjugate vaccines market in 2024. This leadership is supported by well-established immunization frameworks, high healthcare expenditure, and favorable reimbursement policies. Moreover, the region benefits from early adoption of advanced vaccines and robust government initiatives aimed at disease prevention and public health protection.

Who are the key players shaping the competitive landscape?

Leading companies in the conjugate vaccines market include Pfizer Inc., Merck & Co., Inc., GSK, Sanofi, Serum Institute of India, Daiichi Sankyo Company Limited, Panacea Biotec, and Biological E. Limited. These organizations are investing in R&D, expanding manufacturing capabilities, and strengthening global distribution networks to meet rising demand.

Neurological Biomarkers Market to Reach $9.91 Billion by 2030, Driven by Precision Neurology and Expanding Clinical Adoption

The global Neurological biomarkers market is projected to grow from USD 5.53 billion in 2025 to USD 9.91 billion by 2030, at a CAGR of 10.7%. This growth reflects the accelerating shift toward precision neurology and data-driven clinical decision-making. Amid the growing global burden of neurological disorders, the role of biomarkers in transforming diagnosis and therapeutic development is becoming increasingly critical. 

Download PDF Brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=153432005

What is driving this strong market momentum?

The increasing prevalence of neurological conditions such as Alzheimer’s and Parkinson’s diseases is intensifying the demand for early and accurate diagnostic tools. At the same time, rising clinical validation and regulatory acceptance of biomarkers are enabling their broader integration into healthcare systems and research frameworks.

Why are genomic biomarkers gaining significant attention?

The genomic biomarkers segment is expected to be the fastest-growing during the forecast period, fueled by advancements in next-generation sequencing (NGS), declining sequencing costs, and expanding applications in precision medicine. These biomarkers are enhancing risk stratification, enabling early disease detection, and playing a pivotal role in patient selection for clinical trials—ultimately improving therapeutic outcomes and development efficiency.

Who is leading the adoption curve?

Pharmaceutical and biotechnology companies accounted for the largest market share by end user in 2024. Their extensive reliance on biomarkers across drug discovery and development processes—including target validation, patient stratification, and companion diagnostics—is a key growth driver. Increasing investments in neurological drug pipelines and the growing use of biomarker-driven clinical trials are further accelerating adoption across both preclinical and clinical stages.

Speak To Analyst:- https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=153432005

Where are the strongest regional opportunities emerging?

North America continues to dominate the neurological biomarkers market, supported by advanced healthcare infrastructure, strong R&D investments, and the presence of leading industry players. The region’s early adoption of precision medicine and favorable regulatory landscape are facilitating faster biomarker development and commercialization, reinforcing its leadership position.

Who are the key players shaping the competitive landscape?

Prominent companies include Abbott, Thermo Fisher Scientific Inc., QIAGEN, Bio-Rad Laboratories, Inc., Merck KGaA, Johnson & Johnson, Quanterix, and Banyan Biomarkers, Inc.. These organizations are investing heavily in advanced biomarker platforms, strategic collaborations, and precision medicine initiatives to strengthen their market position.

Digital Pathology Market to Reach $2.75 Billion by 2030, growth at a 13.5% CAGR

 The global Digital pathology market is projected to grow from USD 1.46 billion in 2025 to USD 2.75 billion by 2030, registering a strong CAGR of 13.5% during the forecast period. This growth highlights the increasing strategic importance of digital pathology in enabling faster, more accurate, and scalable diagnostic solutions. As healthcare systems worldwide shift toward digitization and precision diagnostics, digital pathology is emerging as a transformative force in modern medicine. 

Download PDF Brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=844 

What is driving this rapid transformation in pathology workflows?

The growing demand for remote pathology services, combined with the need for faster and more precise diagnoses, is pushing healthcare providers to adopt digital solutions. AI-based image analysis is playing a pivotal role by enhancing diagnostic accuracy, automating workflows, and reducing turnaround times. At the same time, advancements in whole-slide imaging and cloud-based platforms are enabling seamless collaboration among pathologists across geographies—reshaping how diagnostic services are delivered.

Why is digital pathology gaining traction now?

The rising burden of chronic diseases, particularly cancer, is increasing the demand for high-quality pathology assessments to support treatment decisions. Digital pathology not only enables advanced image analysis but also reduces reliance on physical storage, improves slide retrieval efficiency, and facilitates real-time consultation and second opinions—critical capabilities in today’s fast-paced clinical environments.

How is the market segmented, and where are the growth opportunities?

By type, the human pathology segment is expected to register the highest growth rate during the forecast period. The increasing need for accurate and efficient diagnostic methods in human healthcare, coupled with the growing emphasis on precision medicine, is accelerating adoption. Compared to traditional methods, digital pathology offers enhanced analytical capabilities, streamlined workflows, and improved collaboration, making it a preferred choice for modern diagnostic practices.

Who are the primary adopters of these technologies?

Pharmaceutical and biotechnology companies accounted for the largest share of the market in 2024. Their growing reliance on digital pathology for drug discovery, tissue analysis, and high-throughput screening is driving demand. By leveraging high-resolution imaging and automated analysis, these organizations can accelerate research timelines, improve candidate selection, and enhance overall R&D productivity.

Where is the market witnessing the strongest momentum? North America dominated the global digital pathology market in 2024, supported by robust investments in healthcare technologies, a high prevalence of chronic diseases, and well-established healthcare infrastructure. The region’s strong ecosystem of research institutions and industry leaders continues to foster innovation and rapid adoption of digital pathology solutions.

Speak To Analyst:- https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=844 

Who are the key players shaping the competitive landscape?

Leading companies in the digital pathology market include Huron Digital Pathology, Hologic, Inc., Corista, Indica Labs Inc., 3DHISTECH, Objective Pathology Services Limited, OptraSCAN, Sectra AB, Akoya Biosciences, Inc., Hamamatsu Photonics K.K., F. Hoffmann-La Roche Ltd., Apollo Enterprise Imaging, XIFIN, Inc., Proscia Inc., KONFOONG BIOTECH INTERNATIONAL CO., LTD., Glencoe Software, Inc., Aiforia, Paige AI, Inc., Fujifilm Holdings Corporation, Danaher Corporation, Koninklijke Philips N.V., Mikroscan Technologies, Inc., PathAI, Motic Digital Pathology, and Kanteron Systems. These organizations are investing in AI capabilities, cloud infrastructure, and integrated diagnostic platforms to strengthen their market position and drive innovation.

Medical Device Manufacturing Equipment Market to Reach $27.80 Billion by 2030, Driven by Automation and Precision Engineering Demand

The global Medical Device Manufacturing Equipment Market (by Production) is projected to grow from $19.24 billion in 2025 to $27.80 billion by 2030, at a CAGR of 7.6%. This steady growth reflects the increasing need for high-precision manufacturing, regulatory compliance, and scalable production capabilities in an evolving medical device landscape.

 

Download PDF Brochure:-https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=11106438

 

As demand rises for minimally invasive devices and next-generation medical technologies, manufacturers are investing heavily in automation, advanced processing systems, and quality-driven production workflows—positioning manufacturing equipment as a critical enabler of innovation and efficiency.

Material Processing Equipment Anchors Market Leadership

The material processing equipment segment is expected to command the largest share of the market. These systems are essential for cutting, shaping, welding, and assembling medical devices with high precision and consistency.

 

Their strategic importance is amplified by:

• Increasing complexity of modern medical devices

• Stringent global quality and regulatory standards

• Growing adoption of automated and digital manufacturing systems

As manufacturers prioritize accuracy, scalability, and repeatability, material processing technologies remain at the core of production ecosystems.

 

Consumables & Disposables Drive Consistent Demand

By application, consumables & disposables accounted for the largest market share in 2024, driven by their recurring usage and critical role in ensuring sterility and compliance.

These products are indispensable across manufacturing stages, supporting:

• Infection control and product safety

• Regulatory adherence

• Continuous production efficiency

Their single-use nature and high turnover rate ensure a stable and recurring revenue stream, reinforcing their dominance in the market.

 

Europe Leads with Advanced Manufacturing Ecosystem

Europe held the largest regional share in 2024, supported by:

• A strong presence of established medical device OEMs

• Advanced manufacturing infrastructure

• Strict regulatory frameworks driving adoption of high-quality equipment

• Robust R&D investments and favorable government initiatives

This combination positions Europe as a global hub for innovation, precision engineering, and high-standard medical device production.

 

Speak To Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=11106438

Competitive Landscape: Automation and Smart Manufacturing at the Forefront

The market is characterized by strong competition and continuous technological advancement. Leading players include: STERIS (US), Nordson Corporation (US), ENGEL (Austria), Zeiss Group (Germany), Multivac (Germany), Coherent Corp. (US), KUKA AG (Germany), ABB (Switzerland), TRUMPF (Germany), OC Oerlikon Management AG (Switzerland), Arburg (Germany), Stratasys Ltd (US), Plasmatreat (Germany), Nikon Corporation (Japan), and Mitutoyo Corporation (Japan), among others.

 

These companies are actively investing in robotics, additive manufacturing, laser processing, and smart factory solutions to enhance production efficiency and maintain competitive advantage.

Immunoassay Market Poised for Growth, Expected to Reach $47.7 Billion by 2030

 The report "Immunoassay Market by Product (Reagents & Kits, Analyzers), Technology (ELISA, CLIA, Western Blot), Specimen (Blood, Saliva, Urine), Application (Infectious Diseases, Endocrinology), End User (Hospitals & Clinics, Laboratories)—Global Forecast to 2030", is projected to reach USD 47.7 billion by 2030 from USD 35.5 billion in 2025, at a CAGR of 6.1% during the forecast period.

 
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=436
 
Browse

• 570  Market Data Tables
• 65    Figures
• 492  Pages and in-depth TOC on " Immunoassay Market - Global Forecast to 2030”

Some of the prominent key players are:

• Abbott (US),
• F. Hoffmann-La Roche Ltd. (Switzerland),
• Siemens Healthineers AG (Germany),
• Thermo Fisher Scientific Inc. (US),
• Danaher (US), and many more......

Mergers & acquisitions, investments & expansions, partnerships & collaborations, and new product developments are some of the major strategies adopted by these key players to enhance their positions in the Immunoassay Market.

• The immunoassay market, by product, is segmented into reagents & kits and analyzers. In 2024, the reagents and kits segment held the largest market share. This significant share is mainly due to the recurring use of reagents and kits across diagnostic workflows. Unlike analyzers, which are a one-time capital investment used over several years, reagents and kits are consumed with each test, making them essential for daily operations in both centralized labs and decentralized testing environments.
• Based on technology, the immunoassay market is segmented into ELISA, CLIA, IFA, rapid tests, ELISpot, western blotting, and other technologies. In 2024, ELISA (enzyme-linked immunosorbent assay) held the largest market share. ELISA's dominance comes from its versatile diagnostic uses, especially in infectious disease and cancer screening, where high sensitivity and specificity are crucial.
• By end user, the immunoassay market is segmented into hospitals & clinics, clinical laboratories, blood banks, and home care settings. In 2024, hospitals and clinics held the largest market share. This is mainly because they play a central role in performing most diagnostic tests, especially for acute and chronic conditions that need quick and reliable results.
• In 2024, North America led the immunoassay market mainly because of its strong presence of established diagnostic companies and advanced healthcare infrastructure. The US was a key contributor to this regional leadership, driven by high demand for sophisticated immunoassay-based diagnostics in both clinical and research settings.

Inquire Before Buying:- https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=436

The growth of the immunoassay market is mainly driven by several key factors. One of the leading causes is the expanding elderly population, which is closely connected to a rising incidence of chronic and age-related diseases like cancer, diabetes, and heart conditions. This demographic change has increased the demand for early, accurate, and efficient diagnostic tools, where immunoassays play an essential role. Additionally, emerging markets offer new growth opportunities, fueled by increasing R&D investments in these regions, thereby improving the environment for market players.

AI in Clinical Workflow Market to Reach $11.08 Billion by 2030

 The global AI in clinical workflow market is projected to grow from USD 2.78 billion in 2025 to USD 11.08 billion by 2030, at a remarkable CAGR of 31.9%. This rapid growth reflects the accelerating adoption of AI-driven solutions that enhance real-time decision-making while seamlessly integrating into clinical processes. As healthcare systems grapple with increasing data complexity and operational pressures.

Download PDF Brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=175075380 

What is fueling this exponential growth?

The surge in clinical data—from electronic health records to imaging and diagnostic reports—is driving the need for advanced AI tools capable of processing and analyzing large datasets efficiently. Healthcare providers are increasingly adopting workflow-embedded AI solutions that improve accuracy, reduce clinician burden, and enhance patient outcomes without disrupting existing workflows.

Why is the general/multi-specialty segment leading adoption?

General and multi-specialty healthcare settings accounted for the largest market share in 2024 due to their need for comprehensive, end-to-end workflow solutions. These facilities benefit from AI applications across multiple departments, enabling integrated care delivery and operational efficiency, unlike specialty-specific settings that focus on narrower use cases.

How is AI transforming clinical decision-making?

The diagnostics and results interpretation segment dominated the functional landscape in 2024. AI-powered tools are increasingly used to analyze complex clinical data—including medical imaging, lab results, and diagnostic reports—helping clinicians make faster and more accurate decisions. This capability is particularly valuable in high-volume care environments where speed and precision are critical.

What role do hospitals play in market expansion?

Inpatient facilities, particularly hospitals, represent the largest end-user segment. Their high patient volumes, complex care pathways, and extensive documentation requirements create strong demand for AI-enabled workflow solutions. Additionally, hospitals benefit from higher IT budgets and established digital infrastructure, enabling faster adoption of integrated AI platforms.

Speak To Analyst:- https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=175075380 

Regional Insights:

Why does North America lead the market? North America dominates the global AI in clinical workflow market due to its advanced healthcare IT infrastructure and widespread adoption of electronic health record systems. The region also benefits from early adoption of AI technologies, strong presence of leading health tech companies, and a shift toward value-based care models that prioritize efficiency and patient outcomes.

Market Insights:

Key players shaping the market include Microsoft, Epic Systems Corporation, Oracle, Koninklijke Philips N.V., Siemens Healthineers AG, GE Healthcare, Optum, Inc., Viz.ai, Inc., Aidoc Medical Ltd., and Qure.ai Technologies Pvt. Ltd., among others. These companies are focusing on AI innovation, strategic partnerships, and workflow integration to strengthen their market presence.

As AI continues to redefine clinical workflows, healthcare stakeholders must embrace intelligent automation and data-driven decision-making to stay competitive. To explore in-depth market insights, emerging trends, and strategic opportunities, access the full report today.

IVD Quality Control Market to Reach $2.15 Billion by 2030

  The global IVD Quality Control market is projected to grow from USD 1.65 billion in 2025 to USD 2.15 billion by 2030, at a CAGR of 5.5%. This growth reflects the increasing emphasis on laboratory accreditation, quality assurance, and standardized testing practices worldwide. As diagnostic accuracy becomes a cornerstone of modern healthcare, how are laboratories ensuring consistent and reliable results?

Download PDF Brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=198032582 

What is driving the demand for IVD quality control solutions?

The rising number of accredited clinical laboratories and the growing importance of external quality assessment (EQA) programs are key factors supporting market expansion. Laboratories are increasingly required to comply with stringent standards set by regulatory bodies such as International Organization for Standardization, College of American Pathologists, and Clinical Laboratory Improvement Amendments. These requirements are driving the adoption of robust quality control systems to ensure accuracy, reproducibility, and compliance.

Why are third-party controls dominating the market?

Third-party quality controls accounted for the largest share in 2024 due to their flexibility and independence from instrument manufacturers. These controls are compatible across multiple platforms and reagent lots, offering laboratories cost efficiency, longer shelf life, and consistent analyte stability. Additionally, they provide unbiased performance evaluation, which is critical for regulatory compliance and benchmarking through EQA programs.

Which end users are driving the fastest growth?

Clinical laboratories are expected to witness the highest growth during the forecast period. The increasing volume of diagnostic testing, combined with the adoption of advanced technologies such as molecular diagnostics and high-throughput systems, is driving demand for reliable quality control solutions. Laboratories are prioritizing accuracy and operational efficiency, leading to increased adoption of multianalyte QC products and data management solutions.

How is technology shaping the market landscape?

The integration of automated diagnostic platforms, immunoassays, and molecular diagnostics is enhancing testing capabilities while increasing the need for precise quality control. As testing complexity grows, laboratories are investing in advanced QC solutions to maintain consistency across diverse diagnostic workflows.

Speak To Analyst:- https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=198032582 

Regional Insights:

Why does North America lead the market? North America holds the largest share of the IVD quality controls market, supported by its advanced healthcare infrastructure and strong regulatory environment. High diagnostic testing volumes, widespread adoption of automated systems, and a strong focus on compliance and quality assurance are driving demand for QC solutions in the region. Additionally, the presence of major industry players and continuous innovation further reinforce the region’s leadership position.

Market Insights:

Key players in the IVD quality controls market include Bio-Rad Laboratories, Inc., Thermo Fisher Scientific Inc., Abbott, F. Hoffmann-La Roche Ltd., Siemens Healthineers AG, Danaher Corporation, Sysmex Corporation, and Randox Laboratories Ltd., among others. These companies are focusing on innovation, product expansion, and strategic partnerships to strengthen their market presence.

As quality assurance becomes increasingly critical in diagnostic workflows, stakeholders must invest in advanced QC solutions and compliance-driven strategies. To gain comprehensive insights into market trends, competitive dynamics, and growth opportunities, access the full report today.

Genomic Biomarkers : Rapid advancements in NGS and PCR technologies

 According to recent market analysis, the Genomic Biomarkers Market is projected to grow from USD 29.00 billion in 2025 to USD 50.31 billion by 2030, registering a robust CAGR of 11.6% during the forecast period. This growth reflects the increasing reliance on genomic insights to enhance clinical decision-making and therapeutic outcomes. The global genomic biomarkers market is witnessing strong momentum as precision medicine reshapes modern healthcare and drug development strategies.

Download PDF Brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=48860286 

What is driving this surge, and why is it critical for industry leaders today? 

The expansion of the genomic biomarkers market is closely linked to the growing adoption of genomic testing across oncology, rare diseases, and inherited disorders. Why are organizations prioritizing these technologies? Advances in polymerase chain reaction (PCR) and next-generation sequencing (NGS) are enabling faster, more accurate, and cost-effective genomic analysis, making biomarker-driven diagnostics and therapies more accessible at scale.

Among technologies, next-generation sequencing (NGS) accounted for the largest market share in 2024. How is NGS transforming the landscape? Its ability to analyze hundreds of genes and complex molecular signatures in a single run makes it indispensable for comprehensive tumor profiling and the discovery of prognostic and predictive biomarkers. Hospitals, cancer centers, and pharmaceutical companies are increasingly leveraging NGS to enhance diagnostic precision and accelerate biomarker identification.

From an end-user perspective, pharmaceutical and biotechnology companies emerged as the fastest-growing segment in 2024. What is fueling this growth? These organizations integrate genomic biomarkers throughout the drug development lifecycle—from target discovery and patient stratification to response monitoring and companion diagnostic development. This end-to-end utilization generates consistent testing demand and strengthens the role of biomarkers in advancing personalized therapeutics.

Speak To Analyst:- https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=48860286

Regional Insights:

Where is the market gaining the most traction? North America led the global genomic biomarkers market in 2024, supported by a strong ecosystem of academic medical centers, cancer institutes, and commercial laboratories. The widespread adoption of NGS-based testing, liquid biopsies, and companion diagnostics has reinforced the region’s leadership. Additionally, favorable reimbursement frameworks, government initiatives such as the Cancer Moonshot, and significant investments in biomarker-driven clinical trials continue to drive regional growth.

Key Market Insights:

Key players shaping the competitive landscape include Thermo Fisher Scientific Inc. (US), F. Hoffmann-La Roche Ltd (Switzerland), Illumina, Inc. (US), QIAGEN (Germany/Netherlands), Bio-Rad Laboratories, Inc. (US), Agilent Technologies, Inc. (US), Eurofins Scientific (Luxembourg), and Quanterix (US). These companies are actively advancing innovation through product development, strategic collaborations, and expansion of genomic testing capabilities to meet growing global demand.

Global Catheters Market Set to Reach $45.99 Billion by 2030 Amid Rising Healthcare Demand

 According to MarketsandMarkets™, The report "Catheters Market By Type [Cardiovascular (Electrophysiology, Coronary Balloon, IVUS/OCT), Intravenous (CVC, PIVC, Midline), Urological, Neurovascular], Indication (Cardiac, Vascular, Kidney, Blood Transfusion, IV Medication Delivery and Fluid Management) – Global Forecast to 2030", is projected to reach USD 45.99 billion by 2030, growing from USD 30.53 billion in 2025 at a CAGR of 8.5% during the forecast period.

 
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=6247803
 
Browse

• 455     Market Data Tables
• 67       Figures
• 415     Pages and in-depth TOC on " Catheters Market - Global Forecast to 2030”.

Some of the prominent key players are:

• Boston Scientific Corporation (US),
• Medtronic PLC (Ireland),
• B. Braun SE (Germany),
• Becton Dickinson and Company (US),
• Stryker Corporation (US),
• Abbott Laboratories (US), and many more.....

Mergers & acquisitions, investments & expansions, partnerships & collaborations, and new product developments are some of the major strategies adopted by these key players to enhance their positions in the Catheters Market.

Speak To Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=6247803

• The cardiovascular catheters segment accounted for the largest global catheters market in 2024. It is projected to grow at the highest rate during the forecast period. This growth is fueled by the increasing incidence of heart conditions, such as coronary artery disease, heart failure, and arrhythmias, particularly among older adults.
• The neurovascular conditions segment is projected to grow at the highest CAGR in the global catheters market from 2025 to 2030. This growth is mainly driven by the rising number of neurological disorders, such as stroke, brain aneurysms, and arteriovenous malformations, which often require catheter-based interventions.
• Asia Pacific is projected to witness the fastest growth in the global catheters market during the forecast period, mainly due to the rising prevalence of chronic diseases such as cardiovascular and kidney disorders, and a rapidly aging population. Increasing healthcare awareness, improving access to medical facilities, and expanding government investments in healthcare infrastructure also boost demand for catheter-based procedures.

The catheters market is projected to grow steadily, supported by the rising use of minimally invasive and image-guided procedures in the cardiovascular, urology, and neurology fields. Technological advancements—such as pressure-sensitive and steerable catheters, drug-coated devices, and infection-resistant coatings—enhance treatment effectiveness and lower risks. Integrating AI-based navigation systems and real-time imaging, particularly in interventional cardiology and neurology, improves accuracy in complex procedures. Furthermore, establishing hybrid catheter labs and advanced surgical suites in high-end healthcare facilities enables more sophisticated treatments. These innovations, combined with growing cases of chronic and lifestyle-related conditions, are driving continuous demand and shaping the market’s long-term growth outlook.

Interventional Oncology Market : Growing preference for targeted treatments

According to the latest market analysis, the Interventional Oncology Market is projected to grow from USD 2.75 billion in 2024 to USD 4.24 billion by 2029, registering a CAGR of 9.0% during the forecast period. The global interventional oncology market is witnessing steady expansion as healthcare systems increasingly prioritize minimally invasive, targeted cancer therapies.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=203687164

What is fueling this shift, and why is it critical for healthcare leaders today? 

The growth of interventional oncology is closely linked to the rising global incidence of cancer and the need for precise, less invasive treatment options. How are healthcare providers addressing complex and inoperable tumors? Interventional oncology techniques—such as embolization, thermal ablation, and targeted radiation therapies—offer localized treatment with reduced systemic side effects, improving patient outcomes while lowering hospital burden.

Among devices and consumables, embolization devices are expected to account for the largest market share during the forecast period. Why are these devices leading adoption? Their ability to deliver targeted therapy directly to tumors through minimally invasive procedures such as transarterial chemoembolization (TACE) and radioembolization has significantly improved clinical outcomes, particularly in liver cancer cases. Advances in embolic materials, including drug-eluting beads and radioactive microspheres, have enhanced precision and therapeutic efficacy, further accelerating their adoption.

By cancer type, liver cancer is projected to dominate the market. What makes this segment so critical? The increasing global incidence of hepatocellular carcinoma—driven by chronic hepatitis infections, alcohol consumption, and non-alcoholic fatty liver disease—has intensified demand for effective treatment solutions. Interventional oncology procedures such as TACE, transcatheter arterial radioembolization (TARE), and percutaneous ablation provide targeted tumor control, fewer side effects, and improved survival rates compared to conventional therapies.

From a procedural standpoint, TARE (also known as selective internal radiation therapy or SIRT) is expected to hold the largest share. How does TARE redefine cancer treatment? By delivering Yttrium-90-loaded microspheres directly into the tumor’s blood supply, this technique ensures localized radiation exposure while preserving healthy tissues. Its superior safety profile, better tolerance, and effectiveness in treating unresectable liver cancers and metastatic conditions make it a preferred choice among clinicians.

Hospitals are anticipated to remain the dominant end users in the interventional oncology market. Who is driving adoption at scale? Large hospitals and tertiary care centers, equipped with advanced imaging systems, catheterization labs, and multidisciplinary oncology teams, are at the forefront of implementing these complex procedures. Their ability to provide comprehensive care—from diagnosis to post-treatment follow-up—positions them as primary hubs for interventional oncology services.

Regional Analysis:

Regionally, North America continues to lead the market, supported by advanced healthcare infrastructure, high adoption of cutting-edge technologies, and a growing cancer patient population. Where is demand most concentrated? The United States, with its robust network of specialized cancer centers and skilled interventional radiologists, remains a key contributor to regional growth. Increasing cases of liver, lung, and kidney cancers further reinforce the demand for minimally invasive treatment options.

Speak To Analyst:  https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=203687164

Market Insights:

The interventional oncology market is highly competitive, with key players such as Siemens Healthineers AG (Varian), Medtronic, Boston Scientific Corporation, Terumo Corporation, Merit Medical Systems, Johnson & Johnson MedTech (Ethicon), Stryker, Teleflex Incorporated, AngioDynamics, Cook, Olympus Corporation, and Guerbet driving innovation. How are these companies shaping the market landscape? Through continuous investment in advanced devices, strategic collaborations, and product innovation, they are expanding the scope and effectiveness of interventional oncology treatments globally.

Why This Matters Now:

As healthcare systems shift toward value-based care and precision medicine, interventional oncology is emerging as a strategic pillar in cancer treatment. For C-suite executives and decision-makers, the market presents significant opportunities to invest in advanced technologies, expand oncology capabilities, and improve patient outcomes while optimizing operational efficiency.

Molecular Cytogenetics Market to Reach $1.43 Billion by 2030

 According to MarketsandMarkets™, the global Molecular Cytogenetics Market is projected to grow from USD 1.02 billion in 2025 to USD 1.43 billion by 2030, registering a CAGR of 7.1% during the forecast period. Market growth is primarily driven by the increasing incidence of cancer and genetic disorders, along with a growing emphasis on targeted therapies and personalized medicine.

The rising aging population and the subsequent increase in chronic disease prevalence are amplifying the demand for advanced genetic testing solutions. Additionally, the expanding role of molecular cytogenetics in clinical pathology is accelerating its adoption across healthcare systems, positioning these technologies as critical tools in precision diagnostics.

Download PDF Brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=148469224 

Key Market Insights

By product & service, the kits & reagents segment is expected to register the highest growth during the forecast period. Their widespread adoption in research, diagnostics, and clinical applications is driven by the need for standardized, accurate, and reproducible testing solutions. Ready-to-use kits and specialized reagents streamline laboratory workflows by reducing the need for complex preparation processes, while ongoing innovations in probes and assay technologies continue to expand their application scope.

Technology Trends

By technique, the comparative genomic hybridization (CGH) segment accounted for the largest share of the molecular cytogenetics market and is expected to maintain its dominance. CGH enables the detection of chromosomal abnormalities associated with developmental disorders, congenital anomalies, and cancer. Its ability to analyze copy number variations without the need for cell culturing significantly enhances efficiency and reliability. Advancements in array-based CGH further allow simultaneous, high-resolution analysis of multiple genomic regions, making it a powerful tool in oncology and genetic research.

Regional Outlook

The Asia Pacific region is projected to witness the fastest growth during the forecast period. This growth is supported by rising healthcare investments, increasing awareness of genetic testing, and expanding government initiatives to strengthen healthcare infrastructure. The region is also seeing increased participation from both domestic and global market players through partnerships and expansion strategies.

Speak To Analyst:-https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=148469224 

Competitive Landscape

The molecular cytogenetics market is competitive and innovation-driven, with leading companies focusing on product development, strategic collaborations, and geographic expansion. Key players in this market include Thermo Fisher Scientific Inc., Illumina, Inc., Danaher, F. Hoffmann-La Roche Ltd., Revvity, Abbott, Agilent Technologies, Inc., PacBio, Bio-Rad Laboratories, Inc., and Bio-Techne, among others.

As demand for advanced genetic analysis and precision medicine continues to rise, the molecular cytogenetics market is expected to experience steady growth, supported by technological advancements and expanding clinical applications.

Companion Animal Diagnostics Market to Reach $5.40 Billion by 2031

 According to MarketsandMarkets™, the global Companion Animal Diagnostics Market is projected to grow from USD 3.56 billion in 2026 to USD 5.40 billion by 2031, registering a CAGR of 8.7% during the forecast period. This growth is driven by rising pet ownership, increasing veterinary healthcare expenditure, and rapid advancements in diagnostic technologies.

The growing demand for fast, accurate, and cost-effective diagnostic solutions is transforming veterinary practices and laboratories. The adoption of advanced tools such as AI-powered image analysis, automated analyzers, in-clinic molecular diagnostics, and cloud-connected platforms is enhancing clinical workflows and enabling earlier and more precise disease detection in companion animals.

Download PDF Brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=173823870 

Key Market Drivers

The increasing focus on preventive care, chronic disease monitoring, and personalized veterinary treatment is significantly boosting demand for advanced diagnostic solutions. Technological innovations, including liquid biopsy, improved assay chemistry, and integrated data systems, are enhancing diagnostic accuracy, traceability, and regulatory compliance. Additionally, growing collaboration among diagnostic companies, veterinary laboratories, and technology providers is fostering the development of scalable, data-driven diagnostic ecosystems.

Segment Insights

By application, the clinical pathology segment accounted for the largest market share in 2025. This segment forms the backbone of routine veterinary diagnostics, encompassing hematology, biochemistry, urinalysis, cytology, and electrolyte analysis. Its widespread adoption is driven by high testing volumes, rapid turnaround times, and its critical role in diagnosing infections, metabolic disorders, and chronic diseases in pets.

By end user, the homecare settings segment is expected to register the highest CAGR during the forecast period. The increasing adoption of at-home diagnostic solutions, coupled with rising demand for convenient and continuous pet health monitoring, is driving this segment’s growth. Advancements in digital health tools and remote diagnostics are further supporting this trend.

Regional Outlook

North America accounted for the largest share of the companion animal diagnostics market in 2025. The region’s dominance is attributed to high pet ownership rates, advanced veterinary healthcare infrastructure, and strong adoption of innovative diagnostic technologies. Additionally, increasing awareness of preventive care, availability of pet insurance, and the presence of leading market players are further supporting market growth in this region.

Speak To Analyst:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=173823870 

Competitive Landscape

The companion animal diagnostics market is highly competitive, with leading players focusing on innovation, partnerships, and expansion strategies. Key companies operating in this space include IDEXX Laboratories, Zoetis Services LLC, Mars, Incorporated, bioMérieux, FUJIFILM Corporation, Thermo Fisher Scientific Inc., Neogen Corporation, Virbac, INDICAL BIOSCIENCE GmbH, and Innovative Diagnostics, among others.

As veterinary healthcare continues to evolve toward precision diagnostics and digital integration, the companion animal diagnostics market is expected to witness sustained growth, driven by innovation, increasing pet care awareness, and expanding global demand.

Medical Device Engineering Market to Reach $14.7 Billion by 2029

 According to MarketsandMarkets™,  the global Medical Device Engineering Market is projected to grow from USD 9.0 billion in 2024 to USD 14.7 billion by 2029, registering a strong CAGR of 10.1% during the forecast period. This growth is driven by rapid advancements in healthcare infrastructure, rising healthcare expenditure, and increasing demand for innovative, cost-effective medical technologies worldwide.

The emerging economies such as China, India, and Brazil are playing a pivotal role in shaping market expansion. Significant investments in healthcare modernization, improved access to medical services, and the adoption of advanced technologies are creating substantial opportunities for engineering service providers. These players are increasingly offering end-to-end solutions, including product design, development, and regulatory compliance, to meet evolving regional needs.

Download PDF Brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=266679113 

Key Market Drivers

The rising demand for technologically advanced medical devices, coupled with the growing complexity of regulatory requirements, is accelerating the need for specialized engineering services. Additionally, the increasing integration of artificial intelligence (AI), connectivity, and mobility solutions in medical devices is transforming the landscape, enabling enhanced patient outcomes and operational efficiency.

Segment Insights

By service type, the software development & testing services segment is expected to witness the fastest growth during the forecast period. The surge in AI-enabled medical devices and digital health solutions is driving demand for robust software platforms and rigorous validation processes to ensure clinical accuracy, safety, and compliance with regulatory standards.

By device type, the diagnostic imaging equipment segment is projected to experience the most rapid expansion. The growing adoption of minimally invasive procedures, supported by high-resolution and 3D imaging technologies, is significantly boosting demand for advanced imaging systems. Integration of AI and machine learning further enhances diagnostic precision and procedural outcomes.

Regional Outlook

The Asia Pacific region is anticipated to record the highest growth rate during the forecast period. The region’s emergence as a global hub for medical tourism, combined with cost-effective healthcare services and advanced medical facilities, is attracting a large international patient base. This influx is increasing demand for cutting-edge medical devices, thereby driving the need for sophisticated engineering services to support innovation and deployment.

Speak To Analyst:- https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=266679113

Competitive Landscape

The medical device engineering market is highly competitive, with companies focusing on strategic initiatives such as partnerships, acquisitions, product launches, and geographic expansion. Key players include L&T Technology Services Limited, Infosys Limited, HCL Technologies Limited, Cyient, Wipro, Tech Mahindra Limited, Tata Consultancy Services Limited, Flex Ltd., Capgemini, Alten Group, Accenture, and Veranex, among others.

As healthcare systems worldwide continue to evolve toward digitalization and precision medicine, the demand for specialized engineering expertise is expected to rise, positioning the medical device engineering market for sustained growth in the coming years.

Chromatography Accessories & Consumables Market to Reach $8.74 Billion by 2030

 According to the latest report, “Chromatography Accessories & Consumables Market by Technology (GC, HPLC, UPLC, LPLC, Flash), Product (Columns, Detectors, Autosamplers, Vials, Septa, Degassers), End User (Pharma-Biopharma, Academia, F&B, O&G) – Global Forecasts to 2030,” the market is projected to grow from USD 6.10 billion in 2025 to USD 8.74 billion by 2030, at a CAGR of 7.5%.

Download PDF Brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=1294 

What is driving the sustained growth of this market, and why is it increasingly relevant for industry leaders?

The expansion is fueled by rising R&D investments across pharmaceutical and biopharmaceutical sectors, along with the growing adoption of hyphenated chromatography techniques that enhance analytical precision. Additionally, the increasing application of chromatography in food safety testing and environmental analysis is elevating its role as a critical tool for regulatory compliance and public health assurance.

How are evolving industry requirements shaping demand? The need for high-throughput, accurate, and scalable analytical solutions is driving the adoption of advanced chromatography systems and consumables. Chromatography plays a pivotal role in drug discovery and development processes, enabling efficient separation, identification, and quantification of compounds—making it indispensable for innovation-driven industries.

Where are the emerging opportunities? Untapped markets in developing regions, coupled with increased outsourcing of research activities, are creating new growth avenues. At the same time, competitive dynamics among key players are encouraging innovation and strengthening brand differentiation strategies.

Segment Insights:

Why is liquid chromatography leading the technology segment? Liquid chromatography is expected to dominate the market throughout the forecast period due to its versatility, flexibility, and broad application range. Techniques such as high-performance liquid chromatography (HPLC), ultra-performance liquid chromatography (UPLC), flash chromatography, and low-pressure liquid chromatography (LPLC) are widely used for high-throughput purification and analysis, supporting large-scale laboratory operations and industrial workflows.

What makes columns the largest product segment? In 2024, the columns segment accounted for the largest share of the market, as chromatographic separation occurs within the column itself, making it a critical component of any system. Increasing concerns related to food and water safety are further driving demand for high-performance columns, reinforcing their central role in analytical processes.

Regional Insights:

Where is the fastest growth expected globally? The Asia Pacific region is projected to register the highest CAGR during the forecast period. What factors are contributing to this growth? Rising outsourcing of drug discovery and development activities to cost-efficient markets, coupled with the rapid expansion of the biopharmaceutical industry, is driving regional demand. Countries such as China, India, South Korea, Taiwan, and Singapore are emerging as key hubs for analytical and research activities.

Speak To Analyst :- https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=1294 

Who are the key players shaping the competitive landscape?

Leading companies in the chromatography accessories & consumables market include Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Waters Corporation, Thermo Fisher Scientific Inc., Jasco International Co. Ltd., PerkinElmer Inc., Bruker, Restek Corporation, Shimadzu Corporation, Avantor, Inc., and Merck KGaA. These organizations are focusing on product innovation, portfolio expansion, and strategic collaborations to strengthen their global presence.

How will the market evolve in the coming years? As industries increasingly prioritize quality, compliance, and efficiency, demand for advanced chromatography consumables and accessories is expected to rise. Companies that invest in high-performance technologies and expand into emerging markets will be better positioned to capture long-term growth opportunities.